North American Prodromal Synucleinopathy Consortium
(NAPS Trial)
Trial Summary
What is the purpose of this trial?
This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.
Research Team
Bradley Boeve, MD
Principal Investigator
Mayo Clinic
Yo-El Ju, MD
Principal Investigator
Washington University School of Medicine
Eligibility Criteria
Inclusion Criteria
Treatment Details
Interventions
- NA (NA)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Washington University School of Medicine
Lead Sponsor
David H. Perlmutter
Washington University School of Medicine
Chief Executive Officer since 2015
MD from Washington University School of Medicine
Paul Scheel
Washington University School of Medicine
Chief Medical Officer since 2022
MD from Washington University School of Medicine
Portland VA Medical Center
Collaborator
University of California, Los Angeles
Collaborator
Dr. Thomas Rando
University of California, Los Angeles
Chief Medical Officer since 2023
MD from UCLA
Amir Naiberg
University of California, Los Angeles
Chief Executive Officer since 2024
JD from UCLA
Massachusetts General Hospital
Collaborator
Dr. William Curry
Massachusetts General Hospital
Chief Medical Officer
MD from Harvard Medical School
Dr. Anne Klibanski
Massachusetts General Hospital
Chief Executive Officer since 2019
MD from Harvard Medical School
National Institute on Aging (NIA)
Collaborator
Dr. Richard J. Hodes
National Institute on Aging (NIA)
Chief Executive Officer since 1993
MD from Harvard Medical School
Dr. Marie Bernard
National Institute on Aging (NIA)
Chief Medical Officer
MD from Harvard Medical School
Stanford University
Collaborator
Dr. Richard A. Miller
Stanford University
Chief Executive Officer since 2023
Stanford University, MD
Dr. Robert Schott
Stanford University
Chief Medical Officer since 2021
University of Michigan, MD
Banner Health
Collaborator
Emory University
Collaborator
Dr. R. Donald Harvey
Emory University
Chief Medical Officer
MD from Emory University School of Medicine
Dr. George Painter
Emory University
Chief Executive Officer since 2013
PhD in Synthetic Organic Chemistry from Emory University
McGill University
Collaborator
Philippe Drouet
McGill University
Chief Executive Officer since 2021
Master of Science and Bachelor in Chemical Engineering from McGill University
Marianne Mancini
McGill University
Chief Medical Officer
BS in Nutritional Sciences from McGill University
University of Minnesota
Collaborator
Shashank Priya
University of Minnesota
Chief Executive Officer since 2023
PhD in Materials Engineering from Penn State
Charles Semba
University of Minnesota
Chief Medical Officer since 2021
MD from the University of Minnesota Medical School